Nymox’s NX-1207 For The Treatment Of Benign Prostatic Hyperplasia In Phase 3 Program

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that results from the most recently completed clinical studies of NX-1207, the Company’s investigational drug for the treatment of benign prostatic hyperplasia (BPH), will be presented on Thursday, September 25 at the 82nd Annual Meeting of the North Central Section of the American Urological Association being held in Chicago. Neil D. Shore, MD, FACS, of Myrtle Beach, SC will make the podium presentation.

More: continued here

Filed under: Prostate on October 1st, 2008